ClinicalTrials.gg
TerminatedNCT03366766Updated Feb 20, 2026Results posted

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

A Phase 2 interventional study of Nivolumab and Cisplatin in Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer and Stage IA Non-Small Cell Lung Carcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Phase 2, Interventional, and Treatment

Why this study was terminated
slow accrual and lack of additional funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 43 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
101st of 120
14 · median 66
Started
2017
with 23 others
Phase 2
66 of 120
16 open now
Registered
58th of 120
by date

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 101st largest by enrollment, is one of 24 that started in 2017, is one of 66 in phase 2, and was the 58th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This phase II trial studies how well Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in treating patients with stage I-IIIA non-small cell lung cancer that can be removed by surgery. Monoclonal antibodies, such as Nivolumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as Cisplatin and Pemetrexed Disodium or Gemcitabine Hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride may work better in treating patients with non-small cell lung cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To estimate major pathologic response (mpCR) in patients with newly diagnosed and untreated non-small cell lung cancer (NSCLC) stage I-IIIA treated with three courses of induction nivolumab added to either cisplatin/pemetrexed or cisplatin/gemcitabine prior to surgery.

SECONDARY OBJECTIVES:

I. Safety. II. Complete pathologic response at all sites of disease. III. Major pathologic response rate at primary site. IV. Clinical complete response rate. V. 1 year progression free survival (PFS). VI. Overall survival.

TERTIARY OBJECTIVES:

I. To explore whether PDL1 expression is associated with treatment response. II. To explore whether there is a net change in the Th1/Th2 ratio (IFN-gamma, IL-4, IL10, etc.) or cell subset frequencies (M2 monocytes, myeloid-derived suppressor cells, etc.) within a patient's peripheral blood either at baseline or in response to treatment is associated with treatment response.

III. To explore whether exosomes or other immune related serum biomarkers change after combination therapy.

IV. To explore the predictive value of serial cell free deoxyribonucleic acid (DNA) levels and response.

V. PD-L1 assessment in tumor.

03

Conditions studied

  • Non-Squamous Non-Small Cell Lung Carcinoma
  • Stage I Non-Small Cell Lung Cancer
  • Stage IA Non-Small Cell Lung Carcinoma
  • Stage IB Non-Small Cell Lung Carcinoma
  • Stage II Non-Small Cell Lung Cancer
  • Stage IIA Non-Small Cell Lung Carcinoma
  • Stage IIB Non-Small Cell Lung Carcinoma
  • Stage IIIA Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed non small cell lung cancer (NSCLC), not previously treated, with a plan to undergo surgery
  • Stage I-IIIA (stage I tumors must be >= 4 cm) per AJCC 8th edition
  • Tumor sample must be available for testing; within 3 months of study enrollment will be used; if archival tissue is unavailable, a fresh biopsy will be taken
  • (ECOG) performance status 0-1
  • While blood cells 2000/ul or more
  • 1500/ul or more
  • 100,000/ul or more
  • 9 g/dl or more; (transfusion permitted)
  • less than or equal to 1.5 x the (except subjects with Gilbert syndrome, who can have total bilirubin \< 3 mg/dl)
  • (AST) and alanine aminotransferase (ALT) less than or equal to 3 x the upper limit of normal
  • (GFR) greater than or equal to 40 ml/min using the formula or serum creatinine less than or equal to 1.5 x (ULN) upper limit of normal
  • Women of should have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 21 days of the study enrollment
  • Women of reproductive potential must use highly effective methods to avoid pregnancy for 23 weeks after the last dose of study drugs; "women of reproductive potential" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not ; menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level more than 40 mIU/mL
  • Men of reproductive potential who are sexually active with women of reproductive potential must use any contraceptive method with a failure rate of less than 1% per year; men who are receiving the study medications will be instructed to adhere to contraception for 31 weeks after the last dose of study drugs; men who are azoospermic do not require contraception
  • All subjects must be able to comprehend and sign a written document

Exclusion criteria

Exclusion Criteria:

  • Patients who have participated in a study with an agent or device within 2 weeks of enrollment
  • Any prior radiotherapy to the lung
  • Any prior treatment for NSCLC
  • Epidermal growth factor receptor (EGFR) or alkaline phosphatase (ALK) activating alteration
  • Any prior therapy with , anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
  • Any history of a sever reaction to any monoclonal antibody
  • Any history of allergy to the study drug components
  • Any concurrent - exceptions include- basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or in situ cervical cancer that has undergone potentially curative therapy; patients with a history of other prior malignancy must have been treated with curative intent and must have remained disease-free for 3 years post-diagnosis
  • Participants with an active disease or any other condition requiring systemic treatment with either within 14 days (> 10 mg daily prednisone equivalent) or other medications within 30 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
  • Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.• Patients with evidence of interstitial lung disease or active, non-infectious pneumonitis. Patients with a history of interstitial lung disease or non-infectious pneumonitis requiring treatment with steroids are also excluded.
  • Patients with a known infection (HIV 1/2 antibodies) or acquired immunodeficiency syndrome (HIV/AIDS), active (e.g., hepatitis B surface antigen [HBsAg] reactive) or (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)
  • Patients who have received a within 30 days prior initiation of the systemic regimen
  • Patients must not be receiving any other investigational agents
  • Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial
  • Women must not be pregnant (as above) or breastfeeding
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Cohort I (nivolumab, cisplatin, pemetrexed disodium)

    Patients with non-squamous lung cancer receive nivolumab IV over 30 minutes, cisplatin IV over 60-120 minutes, and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity

    Biological: Nivolumab · Drug: Cisplatin · Drug: Pemetrexed Disodium

  • Experimental
    Cohort I (nivolumab, cisplatin, gemcitabine hydrochloride)

    Patients with squamous lung cancer receive nivolumab IV over 30 minutes on day 1, cisplatin IV over 60-120 minutes on day 1, and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity.

    Biological: Nivolumab · Drug: Gemcitabine Hydrochloride

Interventions

  • BiologicalNivolumab

    Given IV

    Also known as: BMS-936558, NIVO, Opdivo, ONO-4538

  • Given IV

    Also known as: (SP-4-2)-Diamminedichloroplatinum, Abiplatin, Blastolem, Briplatin, (CDDP) Cis-diammine-dichloroplatinum, Cis-dichloroammine Platinum (II), Metaplatin, Plastistil, Platinol, Platinex, Platinol-AQ VHA Plus, Peyrone's Salt

  • Given IV

    Also known as: Alimta, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt

  • Given IV

    Also known as: Hydrochloride, Difluorodeoxycytidine Hydrochloride, Gemzar

06

What researchers measure

Primary outcomes

  1. Major Pathologic Response (mpCR) Defined as < 10% Viable Tumor

    For the primary endpoint, the major pathologic response rate was calculated as a percentage of patients who achieved a major pathologic response (i.e., \<10% viable tumor) or pathologic complete response. Then, the major pathologic response rate was tested with the exact binomial test under the null hypothesis that the true major pathologic response rate is ≤ 0.19. The corresponding 95% Clopper-Pearson confidence limits were reported too.

    Time frame: Up to 63 days

Secondary outcomes

  1. Number of Adverse Events

    Number of adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Safety data will be summarized descriptively.

    Time frame: Up to 6 months

  2. Progression Free Survival

    The distribution of progression-free survival will be estimated using the Kaplan-Meier method.

    Time frame: At 1 year

  3. Overall Survival

    The distribution of overall survival will be estimated using the Kaplan-Meier method.

    Time frame: Up to 1 year

  4. Overall Clinical Response

    Will be summarized by presence of baseline measurable disease. Overall clinical response measured by Chest CT at 3 timepoints

    Time frame: At Week 10

  5. Overall Clinical Response

    Will be summarized by presence of baseline measurable disease. Overall clinical response measured by Chest CT at 3 timepoints

    Time frame: At Month 3

  6. Overall Clinical Response

    Will be summarized by presence of baseline measurable disease. Overall clinical response measured by Chest CT at 3 timepoints

    Time frame: At Month 6

07

Results

Posted Feb 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)Cohort II (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)
Started410
Completed410
Not completed00

Outcome measures

PrimaryMajor Pathologic Response (mpCR) Defined as < 10% Viable Tumor

For the primary endpoint, the major pathologic response rate was calculated as a percentage of patients who achieved a major pathologic response (i.e., \<10% viable tumor) or pathologic complete response. Then, the major pathologic response rate was tested with the exact binomial test under the null hypothesis that the true major pathologic response rate is ≤ 0.19. The corresponding 95% Clopper-Pearson confidence limits were reported too.

Time frame:
Up to 63 days
Reported as:
Number · Percentage of Participants
Major Pathologic Response (mpCR) Defined as < 10% Viable Tumor
Percentage of ParticipantsCohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)Cohort II (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)Combined Cohort (All Patient Receiving Nivolumab IV
Major Pathologic Response (mpCR) Defined as < 10% Viable Tumor75 (19.4 to 99.4)80.0 (44.4 to 97.5)78.6 (49.2 to 95.3)
SecondaryNumber of Adverse Events

Number of adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Safety data will be summarized descriptively.

Time frame:
Up to 6 months
Reported as:
Number · adverse events
Number of Adverse Events
adverse eventsCohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)Cohort II (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)
Number of Adverse Events12122
SecondaryProgression Free Survival

The distribution of progression-free survival will be estimated using the Kaplan-Meier method.

Time frame:
At 1 year
Reported as:
Number · Probability of Survival
Progression Free Survival
Probability of SurvivalCohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)Cohort II (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)Combined Cohort (All Patients Receiving Nivolumab IV)
Progression Free Survival1.00 (1.00 to 1.00)0.9 (0.47 to 0.99)0.93 (0.59 to 0.99)
SecondaryOverall Survival

The distribution of overall survival will be estimated using the Kaplan-Meier method.

Time frame:
Up to 1 year
Reported as:
Number · Probability of Survival
Overall Survival
Probability of SurvivalCohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)Cohort I (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)Combined Cohort (All Patient Receiving Nivolumab IV)
Overall Survival1.00 (1.00 to 1.00)0.9 (0.47 to 0.99)0.93 (0.59 to 0.99)
SecondaryOverall Clinical Response

Will be summarized by presence of baseline measurable disease. Overall clinical response measured by Chest CT at 3 timepoints

Time frame:
At Week 10
Reported as:
Count of participants · Participants
Overall Clinical Response
ParticipantsCohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)Cohort II (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)Overall (Cohort I and Cohort II)
Complete Response (CR)000
Partial Response (PR)022
Stable Disease (SD)279
Progressive Disease (PD)213
SecondaryOverall Clinical Response

Will be summarized by presence of baseline measurable disease. Overall clinical response measured by Chest CT at 3 timepoints

Time frame:
At Month 3
Reported as:
Count of participants · Participants
Overall Clinical Response
ParticipantsCohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)Cohort II (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)Overall (Cohort I and Cohort II)
Complete Response (CR)134
Partial Response (PR)000
Stable Disease (SD)044
Other202
SecondaryOverall Clinical Response

Will be summarized by presence of baseline measurable disease. Overall clinical response measured by Chest CT at 3 timepoints

Time frame:
At Month 6
Reported as:
Count of participants · Participants
Overall Clinical Response
ParticipantsCohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)Cohort II (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)Overall (Cohort I and Cohort II)
Complete Response (CR)033
Partial Response (PR)000
Stable Disease (SD)268
Other202

Adverse events

Collected over Subjects were followed for an average of 8 months for adverse event data.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)0/4 (0%)0/4 (0%)1/4 (25%)
Cohort II (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)2/10 (20%)1/10 (10%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventCohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)Cohort II (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)
Respiratory FailureRespiratory, thoracic and mediastinal disorders0/41/10
Most frequent other events
Showing 10 of 110
Most frequent other events
EventCohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)Cohort II (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)
Nausea - Grade 1Gastrointestinal disorders1/410/10
Vomiting - Grade 1Gastrointestinal disorders0/47/10
Anorexia - Grade 1Metabolism and nutrition disorders1/46/10
Diarrhea - Grade 1Gastrointestinal disorders0/46/10
Fatigue - Grade1General disorders1/46/10
Pain - Grade 1General disorders0/45/10
Fatigue - Grade 2General disorders0/44/10
Pain Extremity - Grade 1General disorders0/44/10
Sore throat - Grade 1General disorders0/44/10
Alopecia - Grade 1Immune system disorders0/43/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)Cohort II (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)Total
<=18 years000
Between 18 and 65 years41014
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)Cohort II (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)Total
Female347
Male167
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)Cohort II (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)Total
Hispanic or Latino000
Not Hispanic or Latino41014
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort I (Nivolumab, Cisplatin, Pemetrexed Disodium)Cohort II (Nivolumab, Cisplatin, Gemcitabine Hydrochloride)Total
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American000
White3811
More than one race101
Unknown or Not Reported000
08

Study locations

2 sites
  • Abington Hospital - Jefferson Health
    Abington, Pennsylvania 19001, United States
  • Sidney Kimmel Cancer Center at Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Dec 2020, 35 months.

Results were first posted in Feb 2026, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2017
First posted
Dec 8, 2017
StartActual
Dec 20, 2017
Primary completionActual
Dec 6, 2020
CompletionActual
Feb 8, 2023
Results first posted
Feb 20, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03366766
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Responsible party
Sponsor
First posted
Dec 8, 2017
Start date
Dec 20, 2017
Primary completion
Dec 6, 2020
Completion
Feb 8, 2023
Results posted
Feb 20, 2026
Last update
Feb 20, 2026

Study contacts

Rita Axelrod, MD
principal investigator · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Cisplatin · Pemetrexed · Gemcitabine

Start the discussion